Stellarex drug-coated balloon (DCB), featuring EnduraCoat technology, provides top-tier patency to treat common-to-complex lesions with a low drug dose. Low clinically driven target lesion revascularization rates demonstrate the safety of Stellarex across all patients.
Effective low drug dose matters
Dose excess and particulate downstream possibly results in a delay of wound healing, loss of microcirculation and creation of aneurysms. Stellarex is the only low dose DCB with a statistically significant treatment effect at two years.
Treatment that endures even in complex patients
Stellarex exhibits consistent two-year patency across trials - even in the most complex cases. Now, all patients can experience the power of proven results: • 72.1% patency in ILLUMENATE Pivotal proves only durable two-year RCT results in complex lesions • 43.9% severe calcium is four or five times the rate of severe calcium studied in competitive trials
More ease of use, more efficiencies
Stellarex enhances time savings—even in challenging anatomies and through (or across) previously deployed stents. Decide on the DCB designed for ease of use, and feel the difference in your hands.